<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9866">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835405</url>
  </required_header>
  <id_info>
    <org_study_id>D-LBF001-05-1</org_study_id>
    <nct_id>NCT01835405</nct_id>
  </id_info>
  <brief_title>LiquiBand Versus Dermabond Versus Sutures for Closure of Surgical Wounds</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Medical Solutions (Plymouth) Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Medical Solutions (Plymouth) Ltd</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the cosmetic outcome, effectiveness, user and subject satisfaction, and safety
      of LiquiBand® Flex in relation to DermaBond Advanced™ and conventional sutures for the
      topical closure of surgical wounds.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To compare cosmetic outcomes at follow up</measure>
    <time_frame>3 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cosmesis to be evaluated by a panel of masked evaluators using a modified Hollander Wound Evaluation Scale</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Surgical Incisions</condition>
  <arm_group>
    <arm_group_label>LiquiBand Flex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations.  It may be used in conjunction with, but not in place of deep dermal sutures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermabond Advanced</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sutures (Prolene)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LiquiBand Flex</intervention_name>
    <arm_group_label>LiquiBand Flex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermabond Advanced</intervention_name>
    <arm_group_label>Dermabond Advanced</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sutures (Prolene)</intervention_name>
    <arm_group_label>Sutures (Prolene)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female aged 18 or older on day of enrollment

          -  Scheduled for surgical procedure by a delegated study surgeon

          -  Fresh surgical wound with evenly distributed tension over length of incision

          -  Willing and able to sign informed consent

          -  Agree to return for 2 week (+/- 7 days) and 3 month (90 days +/- 7 days)
             post-procedure follow-up visit

        Exclusion Criteria:

          -  Known sensitivity to cyanoacrylates, formaldehyde or acetone products

          -  Wounds in which incision edges are under high tension or not easily apposed (after
             deep layer suture), or over joints (unless immobilized)

          -  Wounds less than 15mm in length

          -  Wounds in which haemostasis is not able to be achieved, eg, drain is placed or
             Warfarin level &gt;2.5 prior to surgery

          -  Wounds in which deep closure could not be achieved

          -  Surgical procedures involving mucus membranes or eyes

          -  Mental incapacity, dementia, or inability to give informed consent

          -  Pregnant or nursing

          -  Disease related or pharmacologically immuno-compromised
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gary S Rogers, MD</last_name>
    <phone>978-524-7933</phone>
    <email>GARogers@nhs-healthlink.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Care Center, Beverly Hospital</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary S Rogers, MD</last_name>
      <email>GARogers@nhs-healthlink.org</email>
    </contact>
    <investigator>
      <last_name>Gary S Rogers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 18, 2013</lastchanged_date>
  <firstreceived_date>April 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
